Recently, Jiudian Hongyang's active pharmaceutical ingredient, Trazodone Hydrochloride (Y20230001003), has recently been approval by the National Medical Products Administration (NMPA) and successfully passed the review process.

Trazodone Hydrochloride is a serotonin receptor antagonist and reuptake inhibitor (SARI). Clinically, it is used to treat depression, insomnia caused by various factors, as well as generalized anxiety disorder, sexual dysfunction, post-traumatic stress disorder, substance dependence, withdrawal reactions, and obsessive-compulsive disorder. As a  widely prescribed medication for treating depression, anxiety, and other related conditions, clinical trials comparing it with medications like paroxetine and sertraline have shown that Trazodone Hydrochloride sustained-release tablets are safe and effective in treating depression.

With the fast-paced nature of modern life and increasing mental stress, depression has become a common mental illness, and its incidence is rising globally. According to the World Health Organization’s 2023 report, there are more than 380 million people with depression worldwide, with an annual incidence rate of about 3%-5%. In certain countries, the incidence rate may be higher due to economic and cultural differences. In 2023, the domestic market size for Trazodone Hydrochloride reached 700 million yuan, with an annual growth rate exceeding 15% from 2020 to 2023, indicating substantial market potential.

As the demand for antidepressants continues to grow, many pharmaceutical companies are entering the antidepressant market, expanding production capacity, and creating both opportunities and challenges for the Trazodone Hydrochloride active pharmaceutical ingredient sector. Jiudian Hongyang will continue to monitor developments in the Trazodone Hydrochloride API field to ensure a stable supply of medications for the treatment of mental illnesses and contribute to the well-being of patients.